GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » S Biomedics Co Ltd (XKRX:304360) » Definitions » Beneish M-Score

S Biomedics Co (XKRX:304360) Beneish M-Score : -3.29 (As of Apr. 24, 2025)


View and export this data going back to 2023. Start your Free Trial

What is S Biomedics Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.29 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for S Biomedics Co's Beneish M-Score or its related term are showing as below:

XKRX:304360' s Beneish M-Score Range Over the Past 10 Years
Min: -3.32   Med: -3.26   Max: 5.71
Current: -3.29

During the past 8 years, the highest Beneish M-Score of S Biomedics Co was 5.71. The lowest was -3.32. And the median was -3.26.


S Biomedics Co Beneish M-Score Historical Data

The historical data trend for S Biomedics Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

S Biomedics Co Beneish M-Score Chart

S Biomedics Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial -3.23 -3.32 5.71 -3.12 -3.29

S Biomedics Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.12 -2.89 -3.89 -3.02 -3.29

Competitive Comparison of S Biomedics Co's Beneish M-Score

For the Biotechnology subindustry, S Biomedics Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


S Biomedics Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, S Biomedics Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where S Biomedics Co's Beneish M-Score falls into.


;
;

S Biomedics Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of S Biomedics Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8849+0.528 * 1.0237+0.404 * 0.689+0.892 * 1.0477+0.115 * 0.857
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9267+4.679 * -0.133772-0.327 * 1.0157
=-3.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was ₩2,050 Mil.
Revenue was 4449.801 + 3378.274 + 3299.397 + 2606.555 = ₩13,734 Mil.
Gross Profit was 1907.249 + 1755.826 + 1801.717 + 1242.643 = ₩6,707 Mil.
Total Current Assets was ₩29,272 Mil.
Total Assets was ₩44,601 Mil.
Property, Plant and Equipment(Net PPE) was ₩4,475 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩1,725 Mil.
Selling, General, & Admin. Expense(SGA) was ₩2,793 Mil.
Total Current Liabilities was ₩11,770 Mil.
Long-Term Debt & Capital Lease Obligation was ₩9,438 Mil.
Net Income was -1954.742 + -1611.095 + -4018.003 + -1882.438 = ₩-9,466 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ₩0 Mil.
Cash Flow from Operations was -487.029 + -1115.597 + -662.28 + -1235.05 = ₩-3,500 Mil.
Total Receivables was ₩2,211 Mil.
Revenue was 3738.408 + 2256.827 + 4096.599 + 3016.545 = ₩13,108 Mil.
Gross Profit was 1842.987 + 1027.539 + 2316.801 + 1366.397 = ₩6,554 Mil.
Total Current Assets was ₩15,700 Mil.
Total Assets was ₩31,947 Mil.
Property, Plant and Equipment(Net PPE) was ₩4,962 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩1,553 Mil.
Selling, General, & Admin. Expense(SGA) was ₩2,876 Mil.
Total Current Liabilities was ₩7,652 Mil.
Long-Term Debt & Capital Lease Obligation was ₩7,305 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2049.613 / 13734.027) / (2210.728 / 13108.379)
=0.149236 / 0.16865
=0.8849

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6553.724 / 13108.379) / (6707.435 / 13734.027)
=0.499964 / 0.488381
=1.0237

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (29271.504 + 4474.954) / 44600.755) / (1 - (15700.412 + 4961.851) / 31947.219)
=0.243366 / 0.353238
=0.689

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=13734.027 / 13108.379
=1.0477

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1553.45 / (1553.45 + 4961.851)) / (1724.889 / (1724.889 + 4474.954))
=0.238431 / 0.278215
=0.857

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2792.699 / 13734.027) / (2876.258 / 13108.379)
=0.203342 / 0.219421
=0.9267

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((9438.361 + 11769.801) / 44600.755) / ((7304.855 + 7652.118) / 31947.219)
=0.475511 / 0.468178
=1.0157

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-9466.278 - 0 - -3499.956) / 44600.755
=-0.133772

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

S Biomedics Co has a M-score of -3.29 suggests that the company is unlikely to be a manipulator.


S Biomedics Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of S Biomedics Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


S Biomedics Co Business Description

Traded in Other Exchanges
N/A
Address
Seongsui-ro 26-gil, 4th Floor, Wooil Venture Town Building 28, Seongdong-gu, FedEx building, Seoul, KOR, 04797
S Biomedics Co Ltd researches and develops cell therapies for regenerative biomedicine. It owns two platform technologies: Functionally Enhanced Cell Spheroid and Targeted Embryonic Stem Cell Differentiation for developing cell therapy products that overcome the limitations of existing cell therapy products.

S Biomedics Co Headlines

No Headlines